Why the study?
The in vivo antihypertensive activity of SA 18 alkaloid in an adrenaline-induced hypertension model in rats was investigated to explore its potential as a cardiovascular agent.
Does the alkaloid SA18 reduce blood pressure in a rat model of adrenaline-induced hypertension?
Does the alkaloid SA18 reduce blood pressure in a rat model of adrenaline-induced hypertension?
The novel alkaloid SA18 demonstrated significant, dose-dependent antihypertensive activity in an in vivo rat model of adrenaline-induced hypertension, with the 50 mg/kg dose being most effective.
ANTIHIPERTENZIV FAOLLIGI Annotatsiya : Tadqiqotda SA 18 alkaloidining kalamushlarda adrenalin bilan induksiyalangan gipertenziya modelida in vivo antihipertenziv faolligi o'rganildi.Modda turli dozalar (25, 50 va 75 mg/kg)da og'iz orqali yuborilgan.Arterial bosim "Sistola" (Neurobotics, RF) qurilmasi yordamida noinvaziv usulda qayd qilindi.Natijalar shuni ko'rsatdiki, SA18 alkaloidining 50 mg/kg dozasi eng samarali bo'lib, sistolik va diastolik bosimni 1,6 marta kamaytirdi (p<0,05).Ushbu ta'sir, ehtimol, kalsiy ionlarining hujayra membranasi orqali oqimini cheklash bilan bog'liq.SA 18 alkaloidi yurak-qon tomir tizimida antihipertenziv vosita sifatida istiqbolli birikma hisoblanadi.
No takes yet. Share an insight, caveat, or question.
Namangan davlat texnika universiteti (2025) studied Adrenaline-induced hypertension (n=16). SA18 alkaloid vs. Control (adrenaline alone) was evaluated on Systolic and diastolic blood pressure (1.6-fold reduction, p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: